Navigation Links
Vaginal Microbicides Might Help More Men Than Women
Date:7/10/2008

Researchers say clinical trials' design may also mask risk of HIV drug resistance

THURSDAY, July 10 ( HealthDay News) -- A new study questions whether vaginal microbicides being developed to help protect women against HIV infection could lead to new drug resistance from the virus that causes AIDS.

The study, published July 7 in the online issue of Proceedings of the National Academy of Sciences, also shows that, under certain circumstances, men may actually benefit a bit more than women from the microbicides, which are compounds that can be applied inside the vagina.

Drug companies are running clinical trials on some second-generation microbicides based on antiretroviral, or ARV, medicines.

The study by the UCLA AIDS Institute also questions the designs of these trials. The researchers made the conclusions by using mathematical models that simulate clinical trials and population-level transmission of HIV.

Under the scenarios the researchers developed, men were slightly more protected than woman in certain situations. This occurred when the in-trial microbicide, an ARV drug called dapivirine, was only effective about half the time in women -- a situation that could occur if HIV-positive women on microbicides developed drug-resistant strains of HIV that were then less likely to be transmitted to men.

"The antiretroviral drugs within these microbicides are the same as those used to treat people who are infected with HIV, so there is great expectation that these microbicides will be very effective," said first author Dr. David Wilson, of the National Centre in HIV Epidemiology and Clinical Research at Australia's University of New South Wales, in a prepared statement.

"But the concern is that these microbicides are going to lead to drug resistance," he said.

Concerns about drug resistance come from the fact that the current clinical trial drops women from the study if they turn up HIV-positive during monthly screening, the researchers said.

"Since monthly testing will take place in the dapivirine trial, we predict that few, if any, cases of acquired resistance will arise during the trial, even if the drug is readily absorbed (i.e., the microbicide is high risk)," the researchers wrote. "Therefore, our analyses have shown that high-risk microbicides could pass Phase III trials, as their potential to cause resistance will be masked by frequent testing."

More information

The U.S. Department of Health & Human Services has more about HIV prevention drugs.



-- Kevin McKeever



SOURCE: University of California, Los Angeles, news release, July 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
2. Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors
3. IPM Reaches Landmark Agreement with Pfizer to Develop FDA-Approved Antiretroviral Drug as Vaginal Microbicide
4. Antiretroviral Drugs May Prevent Vaginal Transmission of HIV
5. Vaginal progesterone gel may improve infant outcomes and...
6. Researchers develop new tool to predict who will use microbicides
7. ADHD Might Raise Kids Obesity Risk
8. Meditation, Yoga Might Switch Off Stress Genes
9. Could new discovery about a shape-shifting protein lead to a mighty morpheein bacteria fighter?
10. Stem Cells Might Treat Tough Fractures
11. Diabetes Might Help Spur Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vaginal Microbicides Might Help More Men Than Women
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology: